Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
298 participants
INTERVENTIONAL
2025-10-30
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
EDX110 with Standard of Care (SOC)
Diabetic Foot Ulcer (DFU) DFU treatment with EDX110 wound dressing and SOC
EDX110
EDX110 wound dressing system EDX110 is a dressing system comprising two layers that allows the generation of nitric oxide (NO) in situ, enables adequate moisture management and facilitates debridement
Standard of Care (SOC)
Diabetic Foot Ulcer (DFU) DFU treatment with using only traditional Standard of Care (SOC)
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EDX110
EDX110 wound dressing system EDX110 is a dressing system comprising two layers that allows the generation of nitric oxide (NO) in situ, enables adequate moisture management and facilitates debridement
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The participant must have an index ulcer meeting the following characteristics:
1. Non-healing DFU defined as; at least 4 weeks prior to enrolment the ulcer has failed to progress on a healing trajectory.
2. Full-thickness wound; defined as Wagner Diabetic Foot Ulcer Grade 1 - superficial ulcer of skin or subcutaneous tissue.
3. Located on the anatomical foot; defined as distal to the medial or lateral malleolus.
* Presents with or without clinical signs of superficial infection. Infection is defined using International Working Group of the Diabetic Foot (IWGDF) PEDIS classification and for the purpose of inclusion infections must be PEDIS grade 1 (Mild); Infected: At least two of these items are present: Local swelling or induration Erythema \>0.5 but \<2 cm2 around the wound, Local tenderness or pain, Local increased warmth, Purulent discharge.
* Ulcer duration at randomization must be present for ≥1 month but less than \<24 months in duration.
* Post-debridement wound area is ≥0.1 cm2 and ≤25 cm2.
* If two or more ulcers either mono or bilateral are present, the index ulcer must additionally be:
1. The ulcer with the largest wound area, as long as it meets all other criteria.
2. ≥3cm distance from any other ulcer on the affected limb
* Known history of type 1 or type 2 diabetes (confirmed by the subject's medical history).
* HgbA1c \<12% (NGSP) OR 108 mmol/mol (IFCC) OR average blood glucose 298 mg/DL.
* Participant has adequate circulation to the affected extremity as defined by Wound, Ischemia, foot Infection (WIfI) Ischemia grades 0-1 (no PAD to Mild PAD).
* Participants are required to have either.
1. Ankle-Brachial Index (ABI) by Doppler: ≥0.6 OR Toe-Brachial Index (TBI) ≥ 0.5
2. OR Dorsum transcutaneous oxygen test (TcPO2): \>40 mm/Hg
Exclusion Criteria
1. Wagner Grade 2 - ulcers extend into tendon, bone, or capsule
2. Grade 3 - deep ulcer with osteomyelitis, or abscess
3. Grade 4 - partial foot gangrene
4. Grade 5 - whole foot gangrene
* Infections that are classified as:
1. PEDIS 3 (Moderate): Infection with no systemic manifestations and involving: Erythema extending ≥2 cm2 from the wound margin, and/or tissue deeper than skin and subcutaneous tissues (e.g., tendon, muscle, joint, and bone).
2. PEDIS 4 (Severe): All of the above in PEDIS 3 plus manifestations (of the systemic inflammatory response syndrome \[SIRS\]).
3. In addition, any diabetic foot infections with; Confirmed underlying bone involvement (osteomyelitis) based on; imaging (plain X-ray, CT or MRI), clinical examination (exposed bone or positive probe to bone test) or culture/histopathology of a bone specimen
4. OR Cellulitis/lymphangitis/soft tissue gas or necrotizing fasciitis originating from the wound site.
* Tunnelling, Cavity or undermining wounds.
* Known or suspected local skin malignancy at the site of the ulcer.
* A wound that is actively bleeding. This does not exclude enrollment once active bleeding has stopped (hemostasis).
* Gross Foot deformities that would interfere with proper off-loading or proper wound healing i.e. non-active charcot foot, rocker bottom foot, gross digital deformities.
* Active Charcot deformity.
* Wound duration \>2 years.
* Participants receiving any of the following prior therapies. In the last 30 days:
1. Has required systemic corticosteroids \>10mg/kg/day OR
2. Participant has required Chemoradiation (chemotherapy and/or radiation therapy) to treat cancer and is immunocompromised OR
3. Participant is anticipated to require such medications during the study period.
4. Study ulcer treatment with any advanced therapy, including, biomedical or topical growth factors, tissue engineered materials (e.g., Apligraf or Dermagraft), sterilized placental allografts (EpiFix, NovaFix, etc.), or other scaffold materials (e.g., OASIS® Wound Matrix, MatriStem Wound Matrix).
5. Has undergone any amputation to the affected leg.
* Known hypersensitivity to constituents of the product.
* Presence of any condition (including current drug or alcohol abuse, medical or psychiatric condition) that is likely to impair understanding of, or compliance with the study protocol in the judgement of the Investigator.
* Women of childbearing age (women aged \<55 years who have not undergone menopause) who are:
1. Pregnant at time of enrolment
2. Breast-feeding
* Concurrent enrolment in any other study.
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ConvaTec Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christina M Mastandrea, MS
Role: STUDY_DIRECTOR
ConvaTec Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Axentra Bio
Phoenix, Arizona, United States
Clemente Clinical Research
Santa Ana, California, United States
ILD Research Center
Vista, California, United States
Futuro Clinical Trials
McAllen, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WC-24-447
Identifier Type: -
Identifier Source: org_study_id